Partnership to utilise complementary technology platforms to produce a differentiated ADC product

30 Nov 2017

Vaccinex and Catalent Biologics to collaborate on ADC development.

Catalent Pharma Solutions and Vaccinex have announced an agreement to develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag conjugation platform and GPEx cell line engineering technologies, and Vaccinex’s proprietary ActivMAb technology. The collaboration will focus on developing the ADC against an undisclosed cancer target.

Partnership to utilise complementary technology platforms to produce a differentiated ADC product
Catalent's state-of-the-art Madison facility,

Catalent and Vaccinex will evaluate the ADC in various preclinical models and move it into cell line and process development, utilizing Catalent’s proprietary GPEx technology and development and manufacturing capabilities at its state-of-the-art Madison, Wisconsin facility.

“Vaccinex is excited to partner with Catalent Biologics to develop this novel ADC for the treatment of cancer. We feel that by combining an ActivMAb antibody with Catalent’s SMARTag conjugation technology, we can generate a unique, differentiated molecule to treat cancers overexpressing this particular target,” commented Raymond E. Watkins, Senior Vice President and Chief Operating Officer of Vaccinex.

“We are delighted to partner with an innovative company like Vaccinex to develop a product that has the potential to deliver better outcomes for patients,” added Mike Riley, Vice President & General Manager of Catalent Biologics. “The opportunity to leverage these complementary technology platforms provides great promise to produce a differentiated ADC product.”

Catalent’s proprietary SMARTag site-specific protein-modification and linker technologies were developed to enable the generation of homogenous bioconjugates engineered to enhance potency, safety and stability. The technology employs natural post-translational modifications found in human cells to create “chemical handles” at predetermined sites on protein molecules. These sites can then be stably chemically conjugated to many different payloads. The control afforded by the technology enables identification of superior drugs from libraries of differentially designed conjugates. The GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. To date, eight GPEx-based antibody and protein products are approved and marketed, and over 45 therapeutic candidates are currently in the clinic across the world.

ActivMAb is Vaccinex’s antibody discovery and optimization platform. It combines the advantages of both viral panning and cell sorting to enable the efficient identification of high-affinity, fully human antibodies from antibody libraries expressed in mammalian cells. A fusion protein of immunoglobulin heavy chain with a vaccinia membrane protein (Ig-VMP) has been developed that enables efficient expression on the surface of vaccinia virus, an enveloped mammalian virus, as well as on the surface of the infected cell.

Read More

Related news

Catalent to open second clinical supply facility in China

Catalent to open second clinical supply facility in China

14 Nov 2018

Enables broader integrated solutions for global and local customers.

Read more 
EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more 
Record year for pharma packaging and drug delivery innovation

Record year for pharma packaging and drug delivery innovation

13 Nov 2018

Event sees more innovation centralising at the Paris hub with entries for the awards and Start-up Hub opening.

Read more 
Ardena cements growth and expansion with new HQ

Ardena cements growth and expansion with new HQ

12 Nov 2018

Larger headquarters will enable the company to free up space for additional laboratories and further expand capabilities.

Read more 
Virtual manufacturing system training service launches

Virtual manufacturing system training service launches

12 Nov 2018

Trainees are provided with real-world examples of process workflows.

Read more 
Hikma gets injectables foothold in Vietnam

Hikma gets injectables foothold in Vietnam

10 Nov 2018

Acquisition includes Medlac’s product portfolio of 23 injectable products and its pipeline.

Read more 
Concept Life Sciences extends GLP accreditation to support regulatory studies

Concept Life Sciences extends GLP accreditation to support regulatory studies

10 Nov 2018

Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries.

Read more 
Sartorius receives award for outstanding performance in its production chain

Sartorius receives award for outstanding performance in its production chain

8 Nov 2018

Company's manufacturing building for laboratory instruments in Göttingen wins the Global Excellence in Operations Award.

Read more 
Record growth at The Wasdell Group

Record growth at The Wasdell Group

7 Nov 2018

Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.

Read more 
bioLIVE to merge with BioProduction Congress for 2019 event

bioLIVE to merge with BioProduction Congress for 2019 event

7 Nov 2018

BioProduction’s content platform will be added to the bioLIVE exhibition, creating one of the world’s largest event hubs for the bio industry.

Read more